TCON - Tracon Pharmaceuticals, Inc.
Previous close
1.43
1.430 100.000%
Share volume: 0
Last Updated: Thu 27 Jun 2024 08:08:42 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
Fundamental analysis
22%
Profitability
25%
Dept financing
19%
Liquidity
39%
Performance
15%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
-25.99%
6 Months
-94.42%
1 Year
-54.06%
2 Year
-93.67%
Key data
Stock price
$1.43
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.07 - $12.40
52 WEEK CHANGE
-$54.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Charles P. Theuer
Region: US
Website: traconpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: traconpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
TRACON Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody. TRC102, a small molecule that is in Phase II clinical trial for the. treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and gliob
Recent news